AR036057A1 - Compuestos derivados 4-piperazinil indol, su uso, un proceso para prepararlos y composiciones farmaceuticas que los comprenden - Google Patents
Compuestos derivados 4-piperazinil indol, su uso, un proceso para prepararlos y composiciones farmaceuticas que los comprendenInfo
- Publication number
- AR036057A1 AR036057A1 ARP020102239A ARP020102239A AR036057A1 AR 036057 A1 AR036057 A1 AR 036057A1 AR P020102239 A ARP020102239 A AR P020102239A AR P020102239 A ARP020102239 A AR P020102239A AR 036057 A1 AR036057 A1 AR 036057A1
- Authority
- AR
- Argentina
- Prior art keywords
- alkyl
- disorders
- disease
- hydrogen
- thioalkyl
- Prior art date
Links
- -1 INDOL DERIVATIVE COMPOUNDS Chemical class 0.000 title abstract 3
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- 229910052739 hydrogen Inorganic materials 0.000 abstract 4
- 239000001257 hydrogen Substances 0.000 abstract 4
- 125000004435 hydrogen atom Chemical class [H]* 0.000 abstract 4
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 3
- 150000001875 compounds Chemical class 0.000 abstract 3
- 125000004001 thioalkyl group Chemical group 0.000 abstract 3
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 abstract 2
- 125000000217 alkyl group Chemical group 0.000 abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 125000001188 haloalkyl group Chemical group 0.000 abstract 2
- 125000001475 halogen functional group Chemical group 0.000 abstract 2
- 230000002265 prevention Effects 0.000 abstract 2
- YZKSXUIOKWQABW-UHFFFAOYSA-N 4-piperazin-1-yl-1h-indole Chemical compound C1CNCCN1C1=CC=CC2=C1C=CN2 YZKSXUIOKWQABW-UHFFFAOYSA-N 0.000 abstract 1
- 208000024827 Alzheimer disease Diseases 0.000 abstract 1
- 208000006096 Attention Deficit Disorder with Hyperactivity Diseases 0.000 abstract 1
- 208000020925 Bipolar disease Diseases 0.000 abstract 1
- 208000023105 Huntington disease Diseases 0.000 abstract 1
- 208000026139 Memory disease Diseases 0.000 abstract 1
- 208000012902 Nervous system disease Diseases 0.000 abstract 1
- 208000025966 Neurological disease Diseases 0.000 abstract 1
- 208000008589 Obesity Diseases 0.000 abstract 1
- 208000018737 Parkinson disease Diseases 0.000 abstract 1
- 208000028017 Psychotic disease Diseases 0.000 abstract 1
- 125000002252 acyl group Chemical group 0.000 abstract 1
- 239000000556 agonist Substances 0.000 abstract 1
- 125000003545 alkoxy group Chemical group 0.000 abstract 1
- 125000003282 alkyl amino group Chemical group 0.000 abstract 1
- 125000004390 alkyl sulfonyl group Chemical group 0.000 abstract 1
- 125000004397 aminosulfonyl group Chemical group NS(=O)(=O)* 0.000 abstract 1
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 abstract 1
- 125000003118 aryl group Chemical group 0.000 abstract 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 abstract 1
- 208000028683 bipolar I disease Diseases 0.000 abstract 1
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 abstract 1
- 125000006297 carbonyl amino group Chemical group [H]N([*:2])C([*:1])=O 0.000 abstract 1
- 208000015114 central nervous system disease Diseases 0.000 abstract 1
- 125000004093 cyano group Chemical group *C#N 0.000 abstract 1
- 125000004663 dialkyl amino group Chemical group 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 210000001035 gastrointestinal tract Anatomy 0.000 abstract 1
- 125000004441 haloalkylsulfonyl group Chemical group 0.000 abstract 1
- 229910052736 halogen Inorganic materials 0.000 abstract 1
- 150000002367 halogens Chemical group 0.000 abstract 1
- 125000001072 heteroaryl group Chemical group 0.000 abstract 1
- 125000002768 hydroxyalkyl group Chemical group 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- SYSQUGFVNFXIIT-UHFFFAOYSA-N n-[4-(1,3-benzoxazol-2-yl)phenyl]-4-nitrobenzenesulfonamide Chemical class C1=CC([N+](=O)[O-])=CC=C1S(=O)(=O)NC1=CC=C(C=2OC3=CC=CC=C3N=2)C=C1 SYSQUGFVNFXIIT-UHFFFAOYSA-N 0.000 abstract 1
- 235000020824 obesity Nutrition 0.000 abstract 1
- 229940002612 prodrug Drugs 0.000 abstract 1
- 239000000651 prodrug Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 201000000980 schizophrenia Diseases 0.000 abstract 1
- 239000012453 solvate Substances 0.000 abstract 1
- 125000001424 substituent group Chemical group 0.000 abstract 1
- 125000006296 sulfonyl amino group Chemical group [H]N(*)S(*)(=O)=O 0.000 abstract 1
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
- C07D209/40—Nitrogen atoms, not forming part of a nitro radical, e.g. isatin semicarbazone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Obesity (AREA)
- Child & Adolescent Psychology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Pain & Pain Management (AREA)
- Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Indole Compounds (AREA)
- Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
Abstract
Compuestos derivados de 4-piperazinil indol de fórmula general (1), en donde: R1 se selecciona de hidrógeno, halo, haloalquilo y alquilo C1-6; R2 se selecciona de hidrógeno, alquilo C1-6, alcoxilo C1-6 y tioalquilo C1-6; R3 es -SO2-Ar, y Ar se selecciona de arilo y heteroarilo, opcionalmente sustituido con uno o más sustituyentes seleccionados de alquilo inferior, alcoxilo inferior, tioalquilo, halo, haloalquilo, hidroxialquilo, nitro, hidroxilo, ciano, amino, alquilamino, dialquilamino, aminocarbonilo, carbonilamino, alquilsulfonilo, haloalquilsulfonilo, aminosulfonilo, y sulfonilamino; R4 se selecciona de hidrógeno, halógeno, alquilo C1-6, alcoxilo C1-6, tioalquilo C1-6, trifluormetilo, ciano, y acilo; y R5 se selecciona de hidrógeno, bencilo y alquilo C1-6; o isómeros individuales, mezclas racémicas o no racémicas de isómeros, pro-fármacos, o sales farmacéuticamente aceptables o solvatos de los mismos. Su uso para la elaboración de un medicamento para el tratamiento o prevención de una enfermedad que mejora con agonistas 5-HT6, un proceso para preparar los compuestos de fórmula (1) y composiciones farmacéuticas que los comprenden. Particularmente los compuestos de fórmula (1) son útiles para el tratamiento o prevención de trastornos del SNC, tales como por ejemplo, psicosis, esquizofrenia, depresión maníaca, trastornos neurológicos, trastornos de la memoria, trastornos del déficit de la atención, enfermedad de Parkinson, esclerosis lateral amiotrófica, enfermedad de Alzheimer y enfermedad de Huntington; trastornos del tracto gastrointestinal; y obesidad.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US29883401P | 2001-06-15 | 2001-06-15 | |
| US37874802P | 2002-05-08 | 2002-05-08 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR036057A1 true AR036057A1 (es) | 2004-08-04 |
Family
ID=26970893
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP020102239A AR036057A1 (es) | 2001-06-15 | 2002-06-14 | Compuestos derivados 4-piperazinil indol, su uso, un proceso para prepararlos y composiciones farmaceuticas que los comprenden |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US6790848B2 (es) |
| EP (1) | EP1401812B1 (es) |
| JP (1) | JP2005501019A (es) |
| KR (1) | KR20040010709A (es) |
| AR (1) | AR036057A1 (es) |
| AT (1) | ATE331707T1 (es) |
| BR (1) | BR0210411A (es) |
| CA (1) | CA2450245A1 (es) |
| DE (1) | DE60212841T2 (es) |
| ES (1) | ES2268113T3 (es) |
| MX (1) | MXPA03011638A (es) |
| PA (1) | PA8547901A1 (es) |
| PE (1) | PE20030119A1 (es) |
| UY (1) | UY27336A1 (es) |
| WO (1) | WO2002102774A1 (es) |
Families Citing this family (46)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2002032863A1 (en) * | 2000-10-20 | 2002-04-25 | Biovitrum Ab | 2-, 3-, 4-, or 5-substituted-n1-(benzensulfonyl)indoles and their use in therapy |
| US7452888B2 (en) | 2002-03-27 | 2008-11-18 | Glaxo Group Limited | Quinoline derivatives and their use as 5-ht6 ligands |
| DK1587788T3 (da) * | 2002-09-17 | 2007-09-24 | Hoffmann La Roche | 2,7-substituerede indoler og anvendelsen deraf som 5-HT6-modulatorer |
| BRPI0407976A (pt) * | 2003-03-03 | 2006-03-07 | Hoffmann La Roche | tetrahidroisoquinolinas substituìdas em 2,5 e 2,6 para uso como moduladores de 5-ht6 |
| WO2004080407A2 (en) * | 2003-03-07 | 2004-09-23 | Predix Pharmaceuticals Holdings, Inc. | New serotonin modulating compounds and uses therefor |
| ATE407671T1 (de) * | 2003-05-09 | 2008-09-15 | Esteve Labor Dr | Verwendung von sulfonamid-derivate zur herstellung eines medikaments für die vorbeugung oder behandlung von essstörungen |
| ES2219181B1 (es) * | 2003-05-09 | 2005-12-16 | Laboratorios Del Dr. Esteve, S.A. | Uso de derivados de sulfonamidas para la fabricacion de un medicamento para la profilaxis y/o tratamiento de las disfunciones alimentarias. |
| MXPA06000795A (es) | 2003-07-22 | 2006-08-23 | Arena Pharm Inc | Derivados de diaril y arilheteroaril urea como moduladores del receptor 5-ht2a de serotonina utiles para la profilaxis y tratamiento de desordenes relacionados con el mismo. |
| US7795266B2 (en) * | 2003-09-25 | 2010-09-14 | Helton David R | Tetrahydroindolone derivatives for treament of neurological conditions |
| SE0302760D0 (sv) * | 2003-10-20 | 2003-10-20 | Biovitrum Ab | New compounds |
| BRPI0506909A (pt) * | 2004-01-16 | 2007-05-29 | Hoffmann La Roche | derivados de 1-benzil-5piperazin-1-il-3,4 diidro-1h-quinazolin-2-ona e os respectivos derivados de 1h-benzo (1,2,6) tiadiazina-2,2-dióxido e 1,4-diidro-benzo (d) (1,3)oxazin-2-ona como moduladores do receptor de 5-hidroxitriptamina (5-ht) para o tratamento de doenças do sistema nervoso central |
| AU2005291542B2 (en) | 2004-09-30 | 2010-11-04 | F. Hoffmann-La Roche Ag | Compositions and methods for treating cognitive disorders |
| US7713954B2 (en) * | 2004-09-30 | 2010-05-11 | Roche Palo Alto Llc | Compositions and methods for treating cognitive disorders |
| US7678823B2 (en) * | 2004-10-04 | 2010-03-16 | Myriad Pharmaceticals, Inc. | Compounds for alzheimer's disease |
| US9216966B2 (en) | 2004-10-04 | 2015-12-22 | John Manfredi | Compounds for Alzheimer's disease |
| US7538113B2 (en) | 2005-02-18 | 2009-05-26 | Wyeth | 4-substituted imidazo[4,5-c]pyridine antagonists of gonadotropin releasing hormone receptor |
| US7582634B2 (en) | 2005-02-18 | 2009-09-01 | Wyeth | 7-substituted imidazo[4,5-c]pyridine antagonists of gonadotropin releasing hormone receptor |
| US7534796B2 (en) | 2005-02-18 | 2009-05-19 | Wyeth | Imidazo[4,5-b]pyridine antagonists of gonadotropin releasing hormone receptor |
| US7531542B2 (en) | 2005-05-18 | 2009-05-12 | Wyeth | Benzooxazole and benzothiazole antagonists of gonadotropin releasing hormone receptor |
| US7582636B2 (en) | 2005-05-26 | 2009-09-01 | Wyeth | Piperazinylimidazopyridine and piperazinyltriazolopyridine antagonists of Gonadotropin Releasing Hormone receptor |
| MX2008010481A (es) * | 2006-02-17 | 2008-12-19 | Memory Pharm Corp | Compuestos que tienen afinado para el receptor f-ht6. |
| AU2007234399A1 (en) * | 2006-04-04 | 2007-10-11 | Myriad Genetics, Inc. | Compounds for diseases and disorders |
| EP2046741B1 (en) | 2006-07-03 | 2012-10-31 | Proximagen Ltd. | Indoles as 5-ht6 modulators |
| MX2009004898A (es) | 2006-11-09 | 2009-05-19 | Hoffmann La Roche | Derivados de indol y de benzofurano-2-carboxamida. |
| MX2009012471A (es) * | 2007-05-24 | 2010-02-24 | Memory Pharm Corp | Compuestos 4´sustituidos que tienen afinidad al receptor 5-hidroxitriptamina 6. |
| CA2695456A1 (en) * | 2007-08-15 | 2009-02-19 | Robert Dunn | 3' substituted compounds having 5-ht6 receptor affinity |
| EP2219648A4 (en) * | 2007-11-09 | 2010-11-03 | Cenomed Biosciences Llc | TREATMENT OF POSTRAUMATIC STRESS WITH TETRAHYDROINDOLONE ARYLPIPERAZINE COMPOUNDS |
| EP2508177A1 (en) | 2007-12-12 | 2012-10-10 | Glaxo Group Limited | Combinations comprising 3-phenylsulfonyl-8-piperazinyl-1yl-quinoline |
| US20110021538A1 (en) | 2008-04-02 | 2011-01-27 | Arena Pharmaceuticals, Inc. | Processes for the preparation of pyrazole derivatives useful as modulators of the 5-ht2a serotonin receptor |
| US20090264443A1 (en) * | 2008-04-18 | 2009-10-22 | David Helton | Treatment of organophosphate exposure with tetrahydroindolone arylpiperazine compounds |
| US20100016297A1 (en) * | 2008-06-24 | 2010-01-21 | Memory Pharmaceuticals Corporation | Alkyl-substituted 3' compounds having 5-ht6 receptor affinity |
| US20100022581A1 (en) * | 2008-07-02 | 2010-01-28 | Memory Pharmaceuticals Corporation | Pyrrolidine-substituted azaindole compounds having 5-ht6 receptor affinity |
| US20100029629A1 (en) * | 2008-07-25 | 2010-02-04 | Memory Pharmaceuticals Corporation | Acyclic compounds having 5-ht6 receptor affinity |
| US20100056531A1 (en) * | 2008-08-22 | 2010-03-04 | Memory Pharmaceuticals Corporation | Alkyl-substituted 3' compounds having 5-ht6 receptor affinity |
| WO2010062321A1 (en) | 2008-10-28 | 2010-06-03 | Arena Pharmaceuticals, Inc. | Processes useful for the preparation of 1-[3-(4-bromo-2-methyl-2h-pyrazol-3-yl)-4-methoxy-phenyl]-3-(2,4-difluoro-phenyl)-urea and crystalline forms related thereto |
| UA100192C2 (en) * | 2008-11-11 | 2012-11-26 | УАЙТ ЭлЭлСи | 1-(arylsulfonyl)-4-(piperazin-1-yl)-1h-benzimidazoles as 5-hydroxytryptamine-6 ligands |
| US8367676B2 (en) | 2009-06-30 | 2013-02-05 | Astrazeneca Ab | 2-carboxamide-7-piperazinyl-benzofuran derivatives 774 |
| WO2011088836A1 (en) | 2010-01-25 | 2011-07-28 | H. Lundbeck A/S | NOVEL 4-(ARYL-4-SULFONYL)-6,6a,7,8,9,10-HEXAHYDRO-4H-4,8,10a-TRIAZA-ACEPHENANTHRYLENE AND 3-ARYLSULFONYL-6,6a,7,8,9,10-HEXAHYDRO-3H-3,8,10a-TRIAZA-CYCLOPENTA[C]FLUORENE DERIVATIVES AS SEROTONIN 5-HT6 LIGANDS |
| US20120157494A1 (en) * | 2010-12-16 | 2012-06-21 | Harris Iii Ralph New | Isoindolyl compounds |
| CN103380129B (zh) | 2010-12-20 | 2016-04-20 | 阿克图拉姆生命科学股份公司 | 2-甲酰胺-4-哌嗪基-苯并呋喃衍生物 |
| EP3083588B1 (en) | 2013-12-20 | 2020-12-09 | Sunshine Lake Pharma Co., Ltd. | Aromatic heterocyclic compounds and their application in pharmaceuticals |
| US9974785B2 (en) | 2014-07-08 | 2018-05-22 | Sunshine Lake Pharma Co., Ltd. | Aromatic heterocyclic derivatives and pharmaceutical applications thereof |
| RU2017145976A (ru) | 2015-06-12 | 2019-07-15 | Аксовант Сайенсиз Гмбх | Производные диарил- и арилгетероарилмочевины, применимые для профилактики и лечения нарушения поведения во время REM-фазы сна |
| EP3322415A4 (en) | 2015-07-15 | 2019-03-13 | Axovant Sciences GmbH | DIARYL AND ARYLHETEROARYL UREA DERIVATIVES AS MODULATORS OF THE 5-HT2A SEROTONIN RECEPTOR FOR PROPHYLAXIS AND TREATMENT OF HALLUCINATIONS RELATED TO A NEUROGENERATIVE DISEASE |
| WO2017052394A1 (en) | 2015-09-23 | 2017-03-30 | Uniwersytet Jagielloński | Imidazopyridine compounds and their use as 5-ht6 receptor ligands |
| US12157753B2 (en) * | 2019-01-17 | 2024-12-03 | ViiV Healthcare UK (No.4) Limited | Process for preparing Fostemsavir |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS60190761A (ja) | 1984-03-09 | 1985-09-28 | Sagami Chem Res Center | ４−アミノインド−ルの製造方法 |
| DE69417427T2 (de) * | 1993-09-03 | 1999-11-25 | Smithkline Beecham P.L.C., Brentford | Indol- und indolin-derivate als 5ht1d rezeptor antagonisten |
| MX9700693A (es) | 1994-07-26 | 1997-04-30 | Pfizer | Derivados del 4-indol. |
| DZ2376A1 (fr) | 1996-12-19 | 2002-12-28 | Smithkline Beecham Plc | Dérivés de sulfonamides nouveaux procédé pour leurpréparation et compositions pharmaceutiques les c ontenant. |
| US6194410B1 (en) | 1998-03-11 | 2001-02-27 | Hoffman-La Roche Inc. | Pyrazolopyrimidine and pyrazolines and process for preparation thereof |
| US6251893B1 (en) | 1998-06-15 | 2001-06-26 | Nps Allelix Corp. | Bicyclic piperidine and piperazine compounds having 5-HT6 receptor affinity |
| DE19934433A1 (de) * | 1999-07-22 | 2001-01-25 | Merck Patent Gmbh | N-(Indolcarbonyl-)piperazinderivate |
| AU1542201A (en) | 1999-11-05 | 2001-05-14 | Nps Allelix Corp. | Compounds having 5-HT6 receptor antagonist activity |
| SE0002754D0 (sv) * | 2000-07-21 | 2000-07-21 | Pharmacia & Upjohn Ab | New pharmaceutical combination formulation and method of treatment with the combination |
| WO2002032863A1 (en) * | 2000-10-20 | 2002-04-25 | Biovitrum Ab | 2-, 3-, 4-, or 5-substituted-n1-(benzensulfonyl)indoles and their use in therapy |
| CN1222511C (zh) * | 2000-11-02 | 2005-10-12 | 惠氏公司 | 作为5－羟色胺－6配体的1－芳基－或1－烷基磺酰基－杂环基吲哚 |
| ATE337780T1 (de) * | 2000-11-24 | 2006-09-15 | Smithkline Beecham Plc | Indoly-lsulphonyl-verbindungen zur behandlung von störungen des zns |
-
2002
- 2002-06-06 AT AT02780760T patent/ATE331707T1/de not_active IP Right Cessation
- 2002-06-06 CA CA002450245A patent/CA2450245A1/en not_active Abandoned
- 2002-06-06 EP EP02780760A patent/EP1401812B1/en not_active Expired - Lifetime
- 2002-06-06 DE DE60212841T patent/DE60212841T2/de not_active Expired - Fee Related
- 2002-06-06 KR KR10-2003-7016359A patent/KR20040010709A/ko not_active Ceased
- 2002-06-06 BR BR0210411-3A patent/BR0210411A/pt not_active Application Discontinuation
- 2002-06-06 MX MXPA03011638A patent/MXPA03011638A/es unknown
- 2002-06-06 WO PCT/EP2002/006201 patent/WO2002102774A1/en not_active Ceased
- 2002-06-06 ES ES02780760T patent/ES2268113T3/es not_active Expired - Lifetime
- 2002-06-06 JP JP2003505317A patent/JP2005501019A/ja active Pending
- 2002-06-12 PE PE2002000503A patent/PE20030119A1/es not_active Application Discontinuation
- 2002-06-12 PA PA20028547901A patent/PA8547901A1/es unknown
- 2002-06-14 US US10/172,360 patent/US6790848B2/en not_active Expired - Fee Related
- 2002-06-14 AR ARP020102239A patent/AR036057A1/es unknown
- 2002-06-14 UY UY27336A patent/UY27336A1/es not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| WO2002102774A1 (en) | 2002-12-27 |
| CA2450245A1 (en) | 2002-12-27 |
| ATE331707T1 (de) | 2006-07-15 |
| DE60212841D1 (de) | 2006-08-10 |
| US20030045527A1 (en) | 2003-03-06 |
| PA8547901A1 (es) | 2003-12-10 |
| MXPA03011638A (es) | 2004-04-02 |
| EP1401812B1 (en) | 2006-06-28 |
| UY27336A1 (es) | 2002-12-31 |
| BR0210411A (pt) | 2004-08-17 |
| EP1401812A1 (en) | 2004-03-31 |
| JP2005501019A (ja) | 2005-01-13 |
| ES2268113T3 (es) | 2007-03-16 |
| PE20030119A1 (es) | 2003-02-13 |
| KR20040010709A (ko) | 2004-01-31 |
| DE60212841T2 (de) | 2007-06-21 |
| US6790848B2 (en) | 2004-09-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR036057A1 (es) | Compuestos derivados 4-piperazinil indol, su uso, un proceso para prepararlos y composiciones farmaceuticas que los comprenden | |
| AR036233A1 (es) | Un compuesto derivado de indol, su uso, procesos para prepararlo y una composicion farmaceutica que lo comprende | |
| SE0104332D0 (sv) | Therapeutic agents | |
| CO5700824A2 (es) | Nuevos compuestos heterociclicos utiles para el tratamiento de desordenes inflamatorios y alergicos: proceso para su preparacion y composiciones farmaceuticas que los contienen | |
| AR041566A1 (es) | Derivados de indol utiles para el tratamiento de enfermedades | |
| AP1635A (en) | Azabicyclic-substituted fused-heteroaryl compounds for the treatment of disease. | |
| UY26872A1 (es) | Derivados de la 4- fenil piridina | |
| HUP0401876A2 (hu) | Béta2 adrenerg receptor agonista hatású aril-anilin-származékok, valamint ezeket tartalmazó gyógyászati készítmények és alkalmazásuk | |
| TW200745029A (en) | Sulfonamide derivatives exhibiting PGD2 receptor antagonism | |
| AR027437A1 (es) | Derivados de purina | |
| PA8580301A1 (es) | Nuevos derivados de benzoimidazol utiles como agentes antiproliferativos | |
| AR035153A1 (es) | Derivados de carboxamidas y cetonas de dihidrobenzodioxina | |
| KR101796601B1 (ko) | 선택적 히스톤 탈아세틸화 효소 억제제로서의 헤테로시클릭알킬 유도체 화합물 및 이를 포함하는 약제학적 조성물 | |
| NO20025641D0 (no) | Substituerte 1-aminoalkyl-laktamer og deres anvendelse som muscarin-reseptor-antagonister | |
| EA200601194A1 (ru) | Новые производные бензофурана, используемые для профилактики или лечения нарушений, связанных с 5-ht-рецептором | |
| NO20025640D0 (no) | Substituerte 1-aminoalkyl-laktamer og deres anvendelse som muscarin-reseptor-antagonister | |
| HRP20050213A2 (en) | 2,4-substituted indoles and their use as 5-ht6 modulators | |
| MXPA04005426A (es) | Derivados de pirazol de anillos fuisionados. | |
| MXPA04005313A (es) | Derivados de aminotetralin como antagonistas del receptor muscarinico. | |
| AR032622A1 (es) | Compuestos de 4-amino-azepan-3-ona, composiciones farmaceuticas que los comprenden, intermediarios utiles en la sintesis de tales compuestos, procedimiento para la sintesis de dichos compuestos, y uso de tales compuestos en la fabricacion de medicamentos | |
| AR036735A1 (es) | Derivados de 5-metoxi-8-aril-[1,2,4]triazolo[1,5-a]piridina | |
| BRPI0508404A (pt) | derivado de (indol-3-il)-heterociclo, composição farmacêutica, uso de um derivado de (indol-3-il)-heterociclo, e método de tratamento da dor | |
| CO5570673A2 (es) | Compuestos azapoliciclicos condensados con arilo | |
| CA2374643A1 (en) | 1-trifluoromethyl-4-hydroxy-7-piperidinylaminomethylchroman derivatives as substance p antagonists | |
| AR066086A1 (es) | Derivados de dihidro-benzo (b)(1,4)diazepin-2-ona-sulfonamida |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |